Evaluation of the Modified Hybrid-VMAT for multiple bone metastatic cancer

다중표적 뼈 전이암의 하이브리드 세기변조(modified hybrid-VMAT) 방사선치료계획 유용성 평가

  • Jung, Il Hun (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Cho, Yoon Jin (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Chang, Won Suk (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Kim, Sei Joon (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Ha, Jin Sook (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Jeon, Mi Jin (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Jung, In Ho (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Kim, Jong Dea (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Shin, Dong Bong (Department of Radiation Oncology, Gangnam Severance Hospital) ;
  • Lee, Ik Jae (Department of Radiation Oncology, Gangnam Severance Hospital)
  • 정일훈 (강남세브란스병원 방사선종양학과) ;
  • 조윤진 (강남세브란스병원 방사선종양학과) ;
  • 장원석 (강남세브란스병원 방사선종양학과) ;
  • 김세준 (강남세브란스병원 방사선종양학과) ;
  • 하진숙 (강남세브란스병원 방사선종양학과) ;
  • 전미진 (강남세브란스병원 방사선종양학과) ;
  • 정인호 (강남세브란스병원 방사선종양학과) ;
  • 김종대 (강남세브란스병원 방사선종양학과) ;
  • 신동봉 (강남세브란스병원 방사선종양학과) ;
  • 이익재 (강남세브란스병원 방사선종양학과)
  • Published : 2018.12.29

Abstract

Purpose : This study evaluates the usefulness of the Modified Hybrid-VMAT scheme with consideration of background radiation when establishing a treatment plan for multiple bone metastatic cancer including multiple tumors on the same axis. Materials and Methods : The subjects of this study consisted of five patients with multiple bone metastatic cancer on the same axis. The planning target volume(PTV) prescription dose was 30 Gy, and the treatment plan was established using Ray Station(Ray station, 5.0.2.35, Sweden). In the treatment plan for each patient, two or more tumors were set as one isocenter. A volumetric modulated arc therapy(VMAT) plan, a hybrid VMAT(h) plan with no consideration of background radiation, and a modified hybrid VMAT(mh) with consideration of background radiation were established. Then, using each dose volume histogram(DVH), the PTV maximum dose($D_{max}$), mean dose($D_{mean}$), conformity index(CI), and homogeneity index(HI) were compared among the plans. In addition, the organ at risk(OAR) of each treatment site was evaluated, and the total MU(Monitor Unit) and treatment time were also analyzed. Results : The PTV $D_{max}$ values of VMAT, VMAT(h) and VMAT(mh) were 3188.33 cGy, 3526 cGy, and 3285.67 cGy, the $D_{mean}$ values were 3081 cGy, 3252 cGy, and 3094 cGy; the CI values were $1.35{\pm}0.19$, $1.43{\pm}0.12$, and $1.30{\pm}0.06$; the HI values were $1.06{\pm}0.01$, $1.14{\pm}0.06$, and $1.09{\pm}0.02$; and the VMAT(h) OAR value was increased 3 %, and VMAT(mh) OAR value was decreased 18 %, respectively. Furthermore, the mean MU values were 904.90, 911.73, and 1202.13, and the mean beam on times were $128.67{\pm}10.97$, $167.33{\pm}7.57$, and $190.33{\pm}4.51$ respectively. Conclusions : Applying Modified Hybrid-VMAT when treating multiple targets can prevent overdose by correcting the overlapping of doses. Furthermore, it is possible to establish a treatment plan that can protect surrounding normal organs more effectively while satisfying the inclusion of PTV dose. Long-term follow-up of many patients is necessary to confirm the clinical efficacy of Modified Hybrid-VMAT.

목 적 : 동일 선상축(co-axial image)의 다발성 뼈 전이암에 대한 하이브리드 세기변조(modified hybrid-VMAT) 계획의 유용성을 평가하고자 한다. 대상 및 방법 : 동일 선상축의 다발성 뼈 전이암환자 총 5명을 대상으로 치료계획시스템(Ray station, 5.0.2.35, Sweden)을 이용하여 치료계획을 수립하였다. 치료계획용적(planning target volume, PTV) 처방 선량은 30 Gy로 설정하여 총 3가지 치료계획: 용적변조회전치료계획(volumetric modulated arc therapy, VMAT); 배경방사선(background)을 고려하지 않은 하이브리드 용적변조회전치료계획(hybrid VMAT, VMAT(h)); 배경방사선을 고려한 하이브리드 용적변조회전치료계획(modified hybrid VMAT, VMAT(mh))을 비교하였다. 선량용적히스토그램(dose volume histogram, DVH)을 이용하여 PTV의 maximum dose($D_{max}$), mean dose($D_{mean}$), 처방선량지수(conformity index, CI), 선량균질지수(homogeneity Index, HI) 및 손상위험장기(organ at risk, OAR)의 선량을 분석하였다. 또한 monitor unit(MU)와 치료시간(beam on time)을 분석하였다. 결 과 : VMAT, VMAT(h)과 VMAT(mh)의 PTV $D_{max}$는 3188.33 cGy, 3526 cGy, 3285.67 cGy이고, $D_{mean}$은 3081 cGy, 3252 cGy, 3094 cGy이고, CI는 $1.35{\pm}0.19$, $1.43{\pm}0.12$, $1.30{\pm}0.06$이고, HI는 $1.06{\pm}0.01$, $1.14{\pm}0.06$, $1.09{\pm}0.02$로 평가되었다. VMAT(h)과 VMAT(mh)의 OAR은 3 % 증가와 18 % 감소하는 것으로 평가되었다. 추가적으로 평균 MU는 904.90, 911.73, 1202.13 그리고 평균 Beam on time은 $128.67{\pm}10.97$초, $167.33{\pm}7.57$초, $190.33{\pm}4.51$초 소요되었다. 결 론 : 다중표적 치료 시에는 modified Hybrid-VMAT를 적용하면 선량의 겹침이 보정되어 과선량(over dose) 조사되는 것을 방지하는 다중표적을 치료할 수 있다. 그리고 PTV의 선량포함을 만족하면서 주위의 정상장기를 더 효과적으로 보호할 수 있는 치료계획이 가능하다. 또한 modified Hybrid-VMAT의 임상적 효능을 확인하기 위해 많은 수의 환자를 대상으로 한 장기 추적 관찰이 필요하다.

Keywords

References

  1. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet oncol 2005;6:392-400 https://doi.org/10.1016/S1470-2045(05)70206-0
  2. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J NuclMed 2004;45:1358-65
  3. Jobsen JJ, van der Palen J, Ong F, et al. Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat. 2015;153(2):277-83 https://doi.org/10.1007/s10549-015-3538-5
  4. Jobsen JJ, van der Palen J, Ong F, et al. Synchronous, bilateral breast cancer: prognostic value and incidence. Breast. 2003;12(2):83-8 https://doi.org/10.1016/S0960-9776(02)00278-3
  5. Kheirelseid EA, Jumustafa H, Miller N, et al. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2011;126(1):131-40 https://doi.org/10.1007/s10549-010-1057-y
  6. Kim SJ, Lee MJ, Youn SM. Radiation therapy of synchronous bilateral breast carcinoma(SBBC) using multiple techniques. MedDosim.2018;43(1):55-68
  7. Sitaraman Balaji Subramanian KB, Moorthi Thirunavukarasu, Sumana Premkumar. Bilateral Breast Irradiation Using Hybrid Volumetric Modulated Arc Therapy(h-VMAT) Technique: A Planning Case Report. Cureus. 2016;8((12)):e914
  8. T WADASADAWALA M, DNB, B VISARIYA, MD, R SARIN, MD, FRCR, R R UPRETI, MSc, DipRP, S PAUL, MSc, DipRP and R PHURAILATPAM, MSc, DipRP. Use of tomotherapy in treatment of synchronous bilateral breast cancer: dosimetric comparison study. British Journal of Radiology. 2015;2015(88):20140612
  9. Rudra S, Al-Hallaq HA, Feng C, et al. Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys. 2014;15(2):4547
  10. Nicolini G, Clivio A, Fogliata A, et al. Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy. Radiat Oncol. 2009;4:27 https://doi.org/10.1186/1748-717X-4-27
  11. Buwenge M, Cammelli S, Ammendolia I, et al. Intensity modulated radiation therapy for breast cancer: current perspectives. Breast Cancer (Dove Med Press). 2017;9:121-6
  12. Popescu CC, Olivotto IA, Beckham WA, et al. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys. 2010;76(1):287-95 https://doi.org/10.1016/j.ijrobp.2009.05.038
  13. Pasler M, Georg D, Bartelt S, et al. Node-positive left-sided breast cancer: does VMAT improve treatment plan quality w ith respect to IMRT? Strahlenther Onkol. 2013;189(5):380-6 https://doi.org/10.1007/s00066-012-0281-2
  14. Tyran M, Mailleux H, Tallet A, et al. Volumetricmodulated arc therapy for left-sided breast cancer and all regional nodes improves target volumes coverage and reduces treatment time and doses to the heart and left coronary artery, compared with a field-in-field technique. J Radiat Res. 2015;56(6):927-37 https://doi.org/10.1093/jrr/rrv052
  15. Seppala J, Heikkila J, Myllyoja K, et al. Volumetric modulated arc therapy for synchronous bilateral whole breast irradiation - A case study. Rep Pract Oncol Radiother. 2015;20(5):398-402 https://doi.org/10.1016/j.rpor.2015.05.011
  16. Fiorentino A, Mazzola R, Naccarato S, et al. Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. Radiol Med. 2017;122(6):464-71 https://doi.org/10.1007/s11547-017-0741-y
  17. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-98 https://doi.org/10.1056/NEJMoa1209825
  18. Mast ME, van Kempen-Harteveld L, Heijenbrok MW, et al. Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further? Radiother Oncol. 2013;108(2):248-53 https://doi.org/10.1016/j.radonc.2013.07.017
  19. Gagliardi G, Lax I, Ottolenghi A, et al. Long-term cardiac mortality after radiotherapy of breast cancer-application of the relative seriality model. Br J Radiol. 1996;69(825):839-46 https://doi.org/10.1259/0007-1285-69-825-839
  20. Sardaro A, Petruzzelli MF, D'Errico MP, et al. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol. 2012;103(2):133-42 https://doi.org/10.1016/j.radonc.2012.02.008